Current Clinical Trials
To develop an investigational therapy into a fully approved therapeutic option a rigorous “phased” approach is required. In each phase, specific goals must be accomplished before the next phase can begin.
Included in our portfolio of engineered human enzymes with high therapeutic potential are treatment candidates in different phases of development for a variety of cancer indications. Details below:
- A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC) – NCT03371979 – Active, Not Recruiting
Thank you to the patients, families and physicians who contribute to our collective knowledge and to the potential of future therapies by considering involvement in clinical trials.